Biostar Stem Cell Research Institute Submits the Last Supplements Requested by KFDA of Orphan Drug Designation Application for Vascostem, Stem Cell Treatment for Severe Buerger’s Disease

Biostar Stem Cell Research Institute (director: Dr. Jeong-Chan Ra), joint operated by R Bio and Nature Cell, has announced on Jan. 27^th that the last submission of supplements requested by the KFDA regarding Vascostem orphan drug designation application has been completed.

The last complementary measures for the orphan drug designation application of Vascostem, a stem cell treatment for Buerger’s Disease, has been finally taken after working on it for the past year.

“I’m hoping that the last opportunity can be given to patients suffering from intolerable pain and fear of amputation due to ineffective alternatives previously approved for Buerger’s Disease,” said Dr. Jeon-Chan Ra, the director of Biostar Stem Cell Research Institute. He suggested “If it’s hard to make a decision this time as well, we can have a fair but free debate and conduct a survey to decide”

Jan. 26, 2016, The second complementary measures prepared from Biostar Research Institute are being handed over to Eun-Chong Ban, the CEO of R Biostar(on the left)